Table 3.
Any grade treatment associated toxicities attributed to buparlisib or bevacizumab.
| Toxicity | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total |
|---|---|---|---|---|---|
| Attributed to Bevacizumab | |||||
| Hypertension | 0 | 5 | 4 | 0 | 9 |
| Fatigue | 8 | 0 | 0 | 0 | 8 |
| Proteinuria | 1 | 5 | 0 | 0 | 6 |
| Epistaxis | 4 | 1 | 0 | 0 | 5 |
| Anorexia | 3 | 0 | 0 | 0 | 3 |
| Attributed to Buparlisib | |||||
| AST increase | 7 | 3 | 2 | 2 | 14 |
| Fatigue | 7 | 4 | 1 | 0 | 12 |
| Hyperglycemia | 5 | 5 | 1 | 0 | 11 |
| ALT increase | 5 | 1 | 3 | 1 | 10 |
| Diarrhea | 6 | 1 | 1 | 0 | 8 |
| Nausea | 7 | 0 | 1 | 0 | 8 |
| Anorexia | 6 | 1 | 0 | 0 | 7 |
| Anxiety | 5 | 0 | 1 | 0 | 6 |
| Depression | 4 | 1 | 1 | 0 | 6 |
| Lipase increase | 1 | 2 | 3 | 0 | 6 |
| Oral mucositis | 5 | 1 | 0 | 0 | 6 |
| Amylase increase | 4 | 1 | 1 | 0 | 6 |
| Hypertriglyceridemia | 2 | 2 | 1 | 0 | 5 |
| Weight loss | 3 | 2 | 0 | 0 | 5 |
| Rash – acneiform | 4 | 0 | 0 | 0 | 4 |
| Cognitive disturbance | 0 | 3 | 0 | 0 | 3 |
| Dry skin | 2 | 1 | 0 | 0 | 3 |
| Thrombocytopenia | 3 | 0 | 0 | 0 | 3 |
| Rash – maculopapular | 1 | 1 | 1 | 0 | 3 |
| Vomiting | 3 | 0 | 0 | 0 | 3 |
AST=aspartate aminotransferase; ALT= alanine aminotransferase.